Ikarian Capital’s Cogent Biosciences COGT Stock Holding History

Ikarian Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,280	Closed	-$162K	–	191
2025 Q3	$162K	Sell	11,280 -1,024,248	-99%	-$12.1M	0.02%	155
2025 Q2	$7.44M	Buy	+1,035,528	New	+$5.74M	1.43%	26
2023 Q4	–	Sell	-62,766	Closed	-$612K	–	147
2023 Q3	$612K	Hold	62,766	–	–	0.07%	109
2023 Q2	$743K	Hold	62,766	–	–	0.12%	91
2023 Q1	$677K	Hold	62,766	–	–	0.15%	89
2022 Q4	$726K	Sell	62,766 -100,000	-61%	-$1.24M	0.18%	53
2022 Q3	$2.43M	Sell	162,766 -87,234	-35%	-$1.2M	0.48%	54
2022 Q2	$2.26M	Buy	+250,000	New	+$1.71M	0.41%	55
2021 Q4	–	Sell	-30,727	Closed	-$258K	–	202
2021 Q3	$258K	Sell	30,727 -11,035	-26%	-$84.6K	0.02%	200
2021 Q2	$338K	Hold	41,762	–	–	0.03%	198
2021 Q1	$367K	Hold	41,762	–	–	0.01%	263
2020 Q4	$469K	Buy	+41,762	New	+$459K	0.02%	192

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ikarian Capital's COGT Position: Q4 2025 in Review

Ikarian Capital sold out of Cogent Biosciences (COGT) in Q4 2025, closing a stake of 11,280 shares — an estimated $162K sold.

Ikarian Capital first reported a position in COGT in Q4 2020 and held it in 12 quarters. The position peaked at $7.44M in Q2 2025. 267 funds tracked by Wall St. Rank hold COGT as of Q4 2025.

Ikarian Capital reported no remaining Cogent Biosciences position as of Q4 2025 after selling out during the quarter.
Ikarian Capital sold 11,280 Cogent Biosciences shares in Q4 2025, an estimated $162K.
Ikarian Capital first reported a position in Cogent Biosciences in Q4 2020 and held it in 12 quarters.
Ikarian Capital's Cogent Biosciences position peaked at $7.44M in Q2 2025.
267 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.